Novo Nordisk A/S
Novo Nordisk A/S is a Denmark-based pharmaceutical company focused on medicines for diabetes, obesity, and other serious chronic diseases. It develops, manufactures, and markets prescription medicines and related delivery devices through a global commercial network spanning dozens of countries.
Business
Share of revenueInsulin and other treatments used to manage diabetes and related metabolic disease.
Prescription medicines used for chronic weight management and obesity treatment.
Specialty therapies for conditions such as hemophilia and other rare disorders.
Injection pens, delivery systems, and supporting devices used with medicines.
Customers
Novo Nordisk sells primarily to healthcare systems and prescription medicine channels rather than direct consumers. Its main buyers are hospitals, clinics, pharmacies, distributors, and public or private payers that determine access and reimbursement for chronic disease medicines. Demand is driven by long treatment duration, physician prescribing, and reimbursement coverage for diabetes and obesity therapies.
Hospitals, clinics, and specialist centers that prescribe and administer Novo Nordisk medicines.
Wholesale and retail channels that purchase finished medicines and deliver them to patients.
Government and private reimbursement bodies that influence formulary access and uptake.
People using prescribed diabetes, obesity, or rare disease therapies through their providers.
Strategy
Novo Nordisk's strategy centers on scientific innovation in chronic disease treatment, especially diabetes and obesity. It also emphasizes expanding access to medicines, scaling global manufacturing and commercial reach, and advancing a pipeline of therapies intended to sustain its position in metabolic and specialty care.
New therapies and label expansions support long-term franchise renewal in chronic disease markets.
Broader reimbursement and country coverage increase patient reach and support prescription volumes.
A global injectable medicines business requires dependable capacity and distribution.
Share repurchases and treasury management help optimize capital while preserving investment capacity.
Geography
Novo Nordisk markets its products in around 170 countries and operates with a broad international footprint. Its corporate base is in Denmark, while commercial exposure is diversified across major markets including the United States, Europe, and other international regions. This global footprint matters because reimbursement, regulation, and healthcare access vary materially by country and can affect product mix and demand.
Risks
Novo Nordisk faces typical pharmaceutical risks around regulation, pricing, and access, because prescriptions depend on payer coverage and government health policy. Company-specific risks include clinical and pipeline setbacks, manufacturing execution for global biologics supply, and legal or reimbursement disputes such as U.S. pricing matters. As a global branded drug company, it is also exposed to patent competition, product concentration, and impairment risk on acquired or developed intangible assets.
- Drug pricing and reimbursement pressureImpact: HighLikelihood: High
Prescription uptake depends on payer coverage and government pricing policy, especially in the U.S. and other major markets.
Exposure: Diabetes and obesity medicines
- Pipeline and clinical development riskImpact: HighLikelihood: Medium
Late-stage programs can fail, reducing expected future revenues and causing asset write-downs.
Exposure: Intangible pipeline assets
- Legal and administrative disputesImpact: HighLikelihood: Medium
Large pharmaceutical companies face litigation, investigations, and settlement exposure in major markets.
Exposure: U.S. reimbursement and 340B-related matters
- Manufacturing and supply-chain disruptionImpact: MediumLikelihood: Medium
Global biologics and injectable products require reliable production and distribution.
Exposure: Global medicine supply
Accounting
Judgemental itemsA reversal of a previously constrained U.S. rebate provision can materially boost reported sales and operating profit.
Impact: Reported revenue and adjusted sales comparability
Clinical or commercial underperformance can trigger write-downs of pipeline assets such as monlunabant.
Impact: Operating profit and asset carrying values
Management excludes exceptional legal, impairment, and rebate items to show underlying performance.
Impact: Investor interpretation of profitability trends
Share repurchase activity changes equity and per-share calculations over time.
Impact: EPS, share capital, and equity balance
Similar listed companies
Publicly listed companies with a comparable business focus.
NewAmsterdam Pharma Co N.V.
NAMS · Pharmaceutical Preparations
Novartis AG
NVS · Pharmaceutical Preparations
Novartis AG is a Switzerland-based medicines company that discovers, develops, manufactures, and commercializes prescription therapies across a broad range of therapeutic areas.
MediciNova, Inc
MNOV · Pharmaceutical Preparations
MedicNova Inc.
Eli Lilly and Company
LLY · Pharmaceutical Preparations
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products, with a portfolio anchored by diabetes, obesity, oncology, immunology, and neuroscience medicines.
Tandem Diabetes Care, Inc
TNDM · Surgical & Medical Instruments & Apparatus
Tandem Diabetes Care designs and commercializes insulin delivery systems and diabetes technology for people who require intensive insulin therapy.
Viking Therapeutics, Inc.
VKTX · Pharmaceutical Preparations
Viking Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders.
Last updated: 28/09/2026